Concurrent weekly docetaxel and hyperfractionated radiotherapy for advanced head and neck cancer

Anticancer Research

Volumn 26, Issue 5 B, 2006, Pages 3781-3786

  Matsumoto, Fumihiko ^a   Karasawa, Kumiko ^a   Itoh, Shin ^a   Toda, Megumi ^a   Haruyama, Takuo ^a   Furukawa, Masayuki ^a   Ikeda, Katsuhisa ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Docetaxel; Head and neck cancers; Hyperfractionated radiotherapy

Indexed keywords

DOCETAXEL;

ADULT; ADVANCED CANCER; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DERMATITIS; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; KAPLAN MEIER METHOD; LYMPHOCYTOPENIA; MALE; MUCOSA INFLAMMATION; NEUTROPENIA; PAIN; PRIORITY JOURNAL; XEROSTOMIA;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; TAXOIDS; TREATMENT OUTCOME;

EID: 33750718790     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Pignon JP, Bourhis J, Domenge C and Designe L: Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma: three meta-analyses of updated individual data: Lancet 555: 949-955, 2000.
2. Forastiere A A, Berkey B, Maor M et al: Phase II trial to preserve the larynx; induction chemotherapy and radiotherapy versus concomitant chemotherapy versus radiotherapy alone, Intergroup Trial R91-11. Proc Am Soc Clin Oncol 20: 2a (abstr. 4), 2001.
3. Dreyfuss AI, Clark JR, Norris CM, Rossi RM, Lucarini JW, Busse PM et al: Docetaxel; an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 14: 1672-1678, 1996.
4. Hennequin C, Giocanti N and Favaudon V: Interacion of ionizing radiation with paclitaxel and docetaxel in HeLa and SQ20B cells. Cancer Res 15: 1842-1850, 1996.
5. Catimel G, Verweij J, Mattijssen V, Hanauske A, Piccart M, Wanders J et al: Docetaxel (Taxotere); an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Eearly Clinical Trials Group. Ann Oncol 5: 533-537, 1994.
6. Schiff PB, Fant J and Horwitz SB: promotion of microtubules assembly in vitro by taxol. Nature 277: 665-667, 1979.
7. Millross CG, Mason KA, Hunter NR, Chung WK, Peters LJ and Milas L: Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst 88: 1308-1314, 1996.
8. Terasima R, Tolmach LJ: X-ray sensitivity and DNA synthesis in synchronous populations of HeLa cells. Science 140: 490-492, 1963.
9. Hainsworth JD, Burris HA, Erland JB, Thomas M and Greco FA: Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 16: 2164-2168, 1998.
10. Ang KK: Fractionation effects in clinical practice. In: Textbook of Radiation Oncology. Leibel SA, Phillips TL (eds.). Philadelphia: WB Saunders, pp. 26-41, 1998.
11. Fu KK, Pajak TT, Trotti A, Jones CU, Spencer SA, Phillips TL et al: A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiation therapy for head and neck squamous cell carcinoma: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 48: 7-16, 2000.
12. Horiot JC, Fur LR, N'Guyen T, Chenal C, Schraub S, Alfonsi S et al: Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC Cooperative Group of Radiotherapy. Radiother Oncol 25: 231-241, 1992.
13. Airoldi M, Cattel L, Cortesina G, Giordano C, Pedani F, Recalenda V et al: Docetaxel, carboplatin and concomitant radiotherapy for unresectable squamous cell carcinoma of the head and neck: pharmacokinetic and clinical data of a phase III study. Am J Clin Oncol 27: 155-163, 2004.
14. Calais G, Alfonsi M, Bardet E et al: randomized trial of radiation therapy versus concomitant chemotherapy and radiotation therapy for advanced stage oropharynx carcinoma. J Natl Cancer Inst 91: 2081-2086, 1999.
15. Brizel DM, Alsbers M, Fisher S et al: Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 338: 1798-1804, 1998.
16. Merlano M, Vitale V, Rosso R et al: Treatment of advanced squamous cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. N Engl J Med 327: 1115-1121, 1992.
17. Adelstein DJ, Saxton JP, Lavertu P et al: A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in respectable stage III and IV squamous cell head and neck cancer: preliminary results. Head Neck 19: 567-575, 1997.
18. Wendt TG, Gragenbauer GG, Rodel CM et al: Simultaneous radio chemotherapy versus radiotherapy alone in advanced head and neck cancer: A randomized muticenter study. J Clin Oncol 16: 1318-1324, 1998.
19. Nabell L and Spencer S: Docetaxel with concurrent radiotherapy in head and neck cancer. Smin Oncol 30(suppl 18): 89-93, 2003.
20. Ponser MR and Lefebvre JL: Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck. Br J Cancer 88: 11-17, 2003.
21. Haddad R, Colevas AD, Tishler R, Busse P, Goguen L, Sullivan C et al: Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience. Cancer 97: 412-418, 2003.
22. Jeremic B, Shibamoto Y, Milicic B et al: Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 18: 1458-1464, 2000.
23. Bartelink H, Van den Bogaert W, Horiot JC, Jager J and Van Glabbeke M: concomitant cisplatin and radiotherapy in a conventional and modified fractionation schedule in locally advanced head and neck cancer: a randomized phase II EORTC trial. Eur J Cancer 38: 667-673, 2002.
24. Fletcher GH: Clinical dose-response curves of human malignant epithelial tumours. Br J Radiol 46: 1-12, 1973.
25. Perez C, Pilepich M and Zivnuska F: Tumor control in definitive irradiation of localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 12: 523-532, 1986.
26. Wang CC, Blitzer PH and Suite HD: Twice-a-day radiation therapy for head and neck. Cancer 55: 2100-2104, 1985.
27. Akimoto T, Mitsuhashi N, Sakurai H, Takahashi T, Yamakawa M, Hayakawa K et ah Results of radiation therapy for hypopharyngeal carcinomas: impact of accelerated hyperfractionation on prgnosis. Jpn J Clin Oncol 26: 169-174, 1996.
28. Fujii M, Tsukuda M, Satake B, Kubota A, Kida A, Kohno N, Okami K and Inuyama Y: Phase I/II trial of weekly docetaxel and concomitant radiotherapy for squamous cell carcinoma of the head and neck. Int J Clin Oncol 9: 107-112, 2004.
29. Biete A, Grau JJ et al: Concurrent weekly docetaxel and radiotherapy as radical treatment in patients with unresectable locally advanced head and neck cancer. ASCO Meeting Proceedings 515, 2003.
30. Dubben HH, Thames HD and Beck-Bornholdt HP: Tumor volume: a basic and specific response predictor in radiotherapy. Radiother Oncol 47: 167-174, 1998.
31. Grabenbauer GG, Steininger H, Meyer M, Fietkau R, Brunner T, Heimkelmann P et al: Nodal CT density and total tumor volume as prognostic factors after radiation therapy of stage III/IV head and neck cancer. Radiother Oncol 47: 175-183,1998.
32. Johnson CR, Thames HD, Huang DT and Schmidt-Ullrich RK: The tumor volume and clonogen number relationship: tumor control predictions based upon tumor volume estimates derived from computed tomography. Int J Radiat Oncol Biol Phys 33: 281-287, 1995.
33. Bentzen SM and Thames HD: Tumor volume and local control probability: clinical data and radiobiological interpretations. Int J Radiat Oncol Biol Phys 36: 247-251, 1996.
34. Mauer AM, Masters GA, Haraf DJ et al: Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol 16: 159-164, 1998.
35. Calais G, Bardet E, Sire C, Alfonsi M, Bourhis J, Rhein B et al: Radiotherapy with concomitant weekly docetaxel for stage III/IV oropharynx carcinoma. Results of the 98-02 GORTEC phase II trial. Int J Radiat Oncol Biol Phys 58: 161-166, 2004.
36. Suzuki M, Nishimura Y, Nakamatsu K, Kanamori S, Koike R, Kawamoto M et al: Phase I study of weekly docetaxel infusion and concurrent radiation therapy for head and neck cancer. Jpn J Clin Oncol 33: 297-301, 2003.
37. Karasawa K, Shinoda H, Katsui K, Seki K, Kohno M, Hanyu N et al: Radiotherapy with concurrent docetaxel and carboplatin for head and neck cancer. Anticancer Res 22: 3785-3788, 2002.